Market Intelligence, Clinical Progress, and High-Purity Reagents for Multiple Myeloma and Autoimmune Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LY9/CD229 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LY9/CD229 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View LY9 Products |
| Gene Delivery | LY9/CD229 Promise-ORF / Lentivirus Full-length ORF sequence-verified lentiviral particles for stable cell line construction. |
View LY9 Products |
| Benchmark Ab | Anti-LY9/CD229 Recombinant Antibody Recombinant positive control derived from clinical benchmark clones. |
View LY9 Products |
| Validator | LY9/CD229 siRNA Set Target-specific siRNA pool for gene knockdown and target specificity validation. |
View LY9 Products |
| Related Target A | BCMA (TNFRSF17) Primary multiple myeloma co-target; essential for evaluating combination therapies or bispecific modalities. |
View BCMA Products |
| Related Target B | SLAMF7 (CS1) SLAM family homolog; critical for counter-screening to ensure off-target safety. |
View SLAMF7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Cross-Reactivity & Off-Target Binding | Homolog panel proteins (SLAMF1-7) strictly verified by mass spectrometry and sequence alignment. |
| Conformation-Sensitive Binding (CAR-T / Bispecifics) | HEK293-expressed ECD-Fc preserves native post-translational modifications and tertiary structures. |
| Assay Baseline Drift & Interference | Endotoxin-controlled (<1.0 EU/μg) and carrier-free formulations prevent non-specific immune activation. |
| Lack of Validated Positive Controls | Sequence-verified clinical benchmark antibodies available for direct assay calibration. |
Live LY9/CD229 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LY9/CD229 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to CAR-T and T-cell engager (TCE) modalities. Originally identified as a T-cell and B-cell marker, LY9 (CD229) has emerged as a highly specific target for Multiple Myeloma (MM) due to its dense expression on both mature myeloma cells and myeloma stem cells (MSCs), which are frequently implicated in relapse after BCMA-targeted therapies.
As first-generation BCMA-directed CAR-T therapies face resistance through antigen escape, the next wave of R&D is targeting CD229 to achieve deeper, more durable responses. Current clinical and preclinical pipelines are heavily focused on optimizing binder affinity to selectively target CD229-high malignant cells while sparing CD229-low normal lymphocytes, making high-quality recombinant proteins and stable cell lines indispensable for screening.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T Cell Therapy | Academic Institutions, Biotech Startups | Relapsed/Refractory Multiple Myeloma | Stable cell lines expressing native CD229 (Lentivirus-mediated) for flow cytometry-based cytotoxicity assays. |
| Bispecific Antibodies (TCEs) | Biopharma Corporations | Multiple Myeloma, Autoimmune Diseases | Affinity-tuning assays requiring high-purity monomeric CD229 ECD-Fc proteins for SPR/BLI kinetics. |
| Antibody-Drug Conjugates (ADCs) | Preclinical Stage Developers | B-cell Malignancies | Internalization assays requiring sequence-verified, natively glycosylated CD229 antigens. |